Clinical Trials Logo

Clinical Trial Summary

This study evaluate thermal ALD (T-ALD) and plasma-enhance ALD (PE-ALD) processes modified cardiopulmonary bypass (CPB) tubing to investigate anticoagulation properties.


Clinical Trial Description

ECMO is a technique which is currently being used worldwide for providing life support for patients experiencing both pulmonary and cardiac failure. Though ECMO can effectively rescue life at the initial scene, being invasive, complex, resource intensive, and serious related complications developing on the following days of ECMO support have greatly restricted it use. The major causes of ECMO-related mortality and morbidity are serious coagulopathy, either bleeding (7-34%) or thrombosis (8-17%). Contact of high extracorporeal blood flow and the large artificial surfaces plays a critical role leading to the subsequent coagulopathy. Systemic heparin and heparin-bonded circuits is usually used to reduce thrombus. However, non-urgent invasive procedures should be avoided or minimized during that support and regular clinical monitoring to guide the adjustment of optimal dosage is mandatory making the clinical care intensive. Whereas the pharmacological interventions may bring the risk of critical imbalance between hemostasis and thrombosis, efforts to modify the ECMO system focusing on improvement of biocompatibility seem a fundamental way particularly regarding the extended periods of ECMO use. ZrO2 and Al2O3 are more excellent biocompatible and hemocompatible materials compared with PVC (polyvinylchloride) which is the current material of ECMO circuit. Despite the broad applications of ZrO2 and Al2O3 in artificial implants, traditional thin-film coating techniques are unable to deposit these hemocompatible oxides on the inner surface of the PVC tubing in ECMO circuit. In this subproject, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control, excellent conformality, high uniformity, low defect density, good reproducibility, and low deposition temperature. These characteristics clearly accounts for the feasibility to deposit high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface of ECMO tubing, using the ALD technique. The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03662594
Study type Interventional
Source National Taiwan University Hospital
Contact
Status Completed
Phase N/A
Start date March 10, 2018
Completion date April 10, 2018

See also
  Status Clinical Trial Phase
Completed NCT02705976 - Prospective Trial of a Validated Algorithm for Warfarin Dosing N/A
Active, not recruiting NCT04139525 - Comparison of Citrate and Heparin Anticoagulation During Hemodialysis With MCO PES-PVP (Theranova) Membrane N/A
Completed NCT01907048 - Patient and Physician Knowledge of Key Safety Messages
Recruiting NCT03419923 - Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage N/A
Completed NCT03575936 - Enhanced Pharmacist-Managed Anticoagulation Service in a University-based Family Medicine Clinic N/A
Completed NCT02714855 - Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France N/A
Recruiting NCT01314235 - Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel N/A
Withdrawn NCT04059965 - AntiCoagulation Tracking InterVention and Evaluation N/A
Recruiting NCT02987192 - Minimally Invasive Lumbar Aneasthesia Used for Cesarean Section N/A
Completed NCT01477528 - Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)
Recruiting NCT04405232 - Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK
Recruiting NCT02761941 - Excessive Warfarin Anticoagulation - Causes and Consequences N/A
Completed NCT02392104 - Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service N/A
Completed NCT01884337 - Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Phase 4
Recruiting NCT03473132 - Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC) Phase 4
Enrolling by invitation NCT05305612 - Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions Phase 4
Active, not recruiting NCT03910933 - Electronic KIDCLOT Interactive Thrombosis/Thrombophilia Education; A Quality Assurance Initiative
Completed NCT02492828 - Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden N/A
Completed NCT03684395 - Accessibility to New Drugs Versus SOC in Sweden
Completed NCT01124058 - Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial Phase 1